Spots Global Cancer Trial Database for pancreatic neuroendocrine tumor
Every month we try and update this database with for pancreatic neuroendocrine tumor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Nonfunctioning Small (≤2 cm) Neuroendocrine Pancreatic Incidentaloma | NCT03022188 | Neuroendocrine ... | 18 Years - | Société Française d'Endoscopie Digestive | ||
| Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms | NCT03435770 | Pancreatic Canc... Pancreatic Neop... Pancreatic Aden... Pancreatic Neur... Pancreatic Duct... | EUSRA RFA needl... | 21 Years - 99 Years | Singapore General Hospital | |
| EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors | NCT05554744 | Multiple Endocr... Pancreatic Neur... | EUS-guided fine... | 18 Years - 85 Years | Guangxi Medical University | |
| Multicenter Trial of ESK981 in Patients With Select Solid Tumors | NCT05988918 | Pancreatic Aden... Adenosquamous C... Pancreatic Neur... Pancreatic Neur... Gastrointestina... Gastrointestina... Neuroendocrine ... | ESK981 | 18 Years - | University of Michigan Rogel Cancer Center | |
| Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice. | NCT03947762 | Pancreatic Neur... | 18 Years - | Ipsen | ||
| Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor | NCT01845675 | Advanced Well-d... | temozolomide or... | 18 Years - | Peking Union Medical College Hospital | |
| A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor | NCT03204019 | Pancreatic Neur... | Tegafur and Tem... Tegafur and Tem... | 18 Years - | ChineseAMS | |
| Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine Tumours | NCT06121622 | Pancreatic Neur... | 18 Years - | IRCCS San Raffaele | ||
| CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms | NCT03967951 | Pancreatic Neur... | CT radiomic fea... | 18 Years - | IRCCS San Raffaele | |
| A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors | NCT06158516 | Pancreatic Neur... | Surufatinib Placebo | 18 Years - 75 Years | Changhai Hospital | |
| Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | NCT02159989 | Advanced Malign... Fibrolamellar C... Metastatic Mali... Ovarian Carcino... Pancreatic Neur... Recurrent Malig... Refractory Mali... Unresectable So... | Sapanisertib Ziv-Aflibercept | 18 Years - | National Cancer Institute (NCI) | |
| Ki67 Proliferation Index of Pancreatic Neuroendocrine Neoplasia | NCT04753229 | Neuroendocrine ... | 18 Years - | Institut Paoli-Calmettes | ||
| Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver | NCT05610826 | Pancreatic Neur... Pancreas Cancer | cytoreductive s... Lutathera - a s... Peptide recepto... | 18 Years - | University of Chicago | |
| Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors | NCT00804336 | Neuroendocrine ... Carcinoid Tumor Pancreatic Neur... | SOM230 RAD001 | 18 Years - | Dana-Farber Cancer Institute | |
| Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | NCT04119024 | Metastatic Mali... Metastatic Mela... Pathologic Stag... Pathologic Stag... Recurrent Malig... Refractory Mali... Uveal Melanoma Acral Melanoma Neuroendocrine ... Paraganglioma Pheochromocytom... Adrenocortical ... Pancreatic Neur... Thyroid Cancer Breast Cancer Lung Adenocarci... Head and Neck S... | Biopsy Biospecimen Col... Computed Tomogr... Cyclophosphamid... Fludarabine Pho... Fludeoxyglucose... IL13Ralpha2-spe... Magnetic Resona... Positron Emissi... | 18 Years - 70 Years | Jonsson Comprehensive Cancer Center | |
| Pancreatic Neuroendocrine Tumor：Factor of Surgery Influencing Survival | NCT02624154 | Pancreatic Neur... | pancreatectomy | 10 Years - 80 Years | First Affiliated Hospital, Sun Yat-Sen University | |
| Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms | NCT03435770 | Pancreatic Canc... Pancreatic Neop... Pancreatic Aden... Pancreatic Neur... Pancreatic Duct... | EUSRA RFA needl... | 21 Years - 99 Years | Singapore General Hospital | |
| A Bioequivalence Study of Sunitinib Malate Capsules. | NCT05800106 | Gastrointestina... Renal Cell Carc... Pancreatic Neur... | Sunitinib malat... Sunitinib malat... | 18 Years - 45 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease | NCT00970970 | Von Hippel-Lind... Hemangioblastom... Renal Cell Carc... Pheochromocytom... Pancreatic Neur... | 89Zr bevacizuma... | 18 Years - | University Medical Center Groningen | |
| Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Repair or Reconstruction | NCT06024343 | Pancreatic Tumo... Pancreatic Neur... Solid Pseudopap... | MPD Repair or R... | 18 Years - 70 Years | Fudan University | |
| Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors) | NCT03043508 | Genetic Mutatio... MEN1 | Chart Review Questionnaire | 18 Years - | M.D. Anderson Cancer Center | |
| AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors | NCT01024387 | Neuroendocrine ... Carcinoid Tumor Pancreatic Neur... | AMG 479 | 18 Years - | Dana-Farber Cancer Institute | |
| Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | NCT01466036 | Carcinoid Tumor Pancreatic Neur... | Cabozantinib | 18 Years - | Dana-Farber Cancer Institute | |
| Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | NCT03074513 | Appendix Adenoc... Human Papilloma... Human Papilloma... Human Papilloma... Human Papilloma... Neuroendocrine ... Pancreatic Neur... Recurrent Merke... Recurrent Nasop... Recurrent Perit... Recurrent Pleur... Stage III Merke... Stage III Nasop... Stage III Pleur... Stage IV Merkel... Stage IV Nasoph... Stage IV Pleura... Stage IVA Nasop... Stage IVB Nasop... Stage IVC Nasop... Vaginal Squamou... | Atezolizumab Bevacizumab Laboratory Biom... Pharmacological... | 18 Years - | M.D. Anderson Cancer Center | |
| Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors | NCT05040360 | Metastatic Mali... Pancreatic Neur... Stage I Pancrea... Stage II Pancre... Stage III Pancr... | Capecitabine Temozolomide | 18 Years - | SWOG Cancer Research Network | |
| RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors | NCT00576680 | Pancreatic Neur... | RAD001 Temozolomide | 18 Years - | Dana-Farber Cancer Institute | |
| Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | NCT02159989 | Advanced Malign... Fibrolamellar C... Metastatic Mali... Ovarian Carcino... Pancreatic Neur... Recurrent Malig... Refractory Mali... Unresectable So... | Sapanisertib Ziv-Aflibercept | 18 Years - | National Cancer Institute (NCI) | |
| Ki67 Proliferation Index of Pancreatic Neuroendocrine Neoplasia | NCT04753229 | Neuroendocrine ... | 18 Years - | Institut Paoli-Calmettes | ||
| Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001) | NCT06141369 | Adrenal Cortica... Medullary Thyro... Thymic Neuroend... Pancreatic Neur... | individualized ... | 18 Years - | Shanghai Jiao Tong University School of Medicine | |
| Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations | NCT06041009 | Pancreatic Duct... Pancreatic Dise... Pancreatic Elas... Pancreatic Neur... Pancreatitis Pancreatic Neop... | Pancreatic elas... | 18 Years - | Qilu Hospital of Shandong University | |
| Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine Tumours | NCT06121622 | Pancreatic Neur... | 18 Years - | IRCCS San Raffaele | ||
| Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1 | NCT02355535 | Solid Tumor Pancreatic Neur... Neuroendocrine ... | PAC-1 | 18 Years - 85 Years | Vanquish Oncology, Inc. | |
| EUS-FNI for Nonfunctional Pancreatic Neuroendocrine Tumors | NCT05566093 | Nonfunctional P... Pancreatic Neur... Endoscopic Ultr... | EUS-guided etha... EUS-guided laur... | 18 Years - 85 Years | Guangxi Medical University | |
| Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | NCT01466036 | Carcinoid Tumor Pancreatic Neur... | Cabozantinib | 18 Years - | Dana-Farber Cancer Institute | |
| A Bioequivalence Study of Sunitinib Malate Capsules. | NCT05800106 | Gastrointestina... Renal Cell Carc... Pancreatic Neur... | Sunitinib malat... Sunitinib malat... | 18 Years - 45 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors | NCT02759718 | Non Functioning... | Chromogranin A | 19 Years - 80 Years | Asan Medical Center | |
| EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors | NCT05554744 | Multiple Endocr... Pancreatic Neur... | EUS-guided fine... | 18 Years - 85 Years | Guangxi Medical University | |
| Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors | NCT00804336 | Neuroendocrine ... Carcinoid Tumor Pancreatic Neur... | SOM230 RAD001 | 18 Years - | Dana-Farber Cancer Institute | |
| Artificial Intelligence in EUS for Diagnosing Pancreatic Solid Lesions | NCT05476978 | Pancreatic Duct... Pancreatitis, C... Pancreatic Neur... Autoimmune Panc... | EUS-AI model | 18 Years - | Huazhong University of Science and Technology | |
| Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | NCT03074513 | Appendix Adenoc... Human Papilloma... Human Papilloma... Human Papilloma... Human Papilloma... Neuroendocrine ... Pancreatic Neur... Recurrent Merke... Recurrent Nasop... Recurrent Perit... Recurrent Pleur... Stage III Merke... Stage III Nasop... Stage III Pleur... Stage IV Merkel... Stage IV Nasoph... Stage IV Pleura... Stage IVA Nasop... Stage IVB Nasop... Stage IVC Nasop... Vaginal Squamou... | Atezolizumab Bevacizumab Laboratory Biom... Pharmacological... | 18 Years - | M.D. Anderson Cancer Center | |
| A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations | NCT05199584 | Solid Tumors Wi... | ENV-101 (talade... | 18 Years - | Endeavor Biomedicines, Inc. | |
| RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors | NCT00576680 | Pancreatic Neur... | RAD001 Temozolomide | 18 Years - | Dana-Farber Cancer Institute | |
| Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine Tumours | NCT06121622 | Pancreatic Neur... | 18 Years - | IRCCS San Raffaele | ||
| Neoadjuvant PRRT With Y-90-DOTATOC in pNET | NCT05568017 | Pancreatic Neur... | peptide recepto... | 18 Years - | European Institute of Oncology | |
| Neoadjuvant PRRT With Y-90-DOTATOC in pNET | NCT05568017 | Pancreatic Neur... | peptide recepto... | 18 Years - | European Institute of Oncology | |
| Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors | NCT00942682 | Neuroendocrine ... Carcinoid Tumor Pancreatic Neur... | Sorafenib RAD001 | 18 Years - | Dana-Farber Cancer Institute | |
| Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1 | NCT02355535 | Solid Tumor Pancreatic Neur... Neuroendocrine ... | PAC-1 | 18 Years - 85 Years | Vanquish Oncology, Inc. | |
| Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms | NCT03435770 | Pancreatic Canc... Pancreatic Neop... Pancreatic Aden... Pancreatic Neur... Pancreatic Duct... | EUSRA RFA needl... | 21 Years - 99 Years | Singapore General Hospital | |
| Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor | NCT01845675 | Advanced Well-d... | temozolomide or... | 18 Years - | Peking Union Medical College Hospital | |
| Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors) | NCT03043508 | Genetic Mutatio... MEN1 | Chart Review Questionnaire | 18 Years - | M.D. Anderson Cancer Center | |
| Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | NCT05997056 | Neuroendocrine ... NET Pancreatic Neur... Gastrointestina... Pulmonary Neuro... | nab-sirolimus | 18 Years - | Aadi Bioscience, Inc. | |
| A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors | NCT06158516 | Pancreatic Neur... | Surufatinib Placebo | 18 Years - 75 Years | Changhai Hospital | |
| Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice. | NCT03947762 | Pancreatic Neur... | 18 Years - | Ipsen | ||
| Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Repair or Reconstruction | NCT06024343 | Pancreatic Tumo... Pancreatic Neur... Solid Pseudopap... | MPD Repair or R... | 18 Years - 70 Years | Fudan University | |
| Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors | NCT01824875 | Gastrinoma Glucagonoma Insulinoma Islet Cell Carc... Pancreatic Poly... Recurrent Islet... Somatostatinoma | temozolomide capecitabine | 18 Years - | Eastern Cooperative Oncology Group | |
| Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer | NCT04505553 | Appendix Carcin... Colon Carcinoma Esophageal Carc... Gastric Carcino... Liver and Intra... Malignant Diges... Pancreatic Carc... Rectal Carcinom... Small Intestina... Anal Carcinoma Digestive Syste... Digestive Syste... Pancreatic Neur... | Acupuncture The... Acupressure The... Oral Cryotherap... Questionnaire A... Quality-of-Life... | 18 Years - | University of Washington | |
| Comparison of Kimura Versus Warshaw Technique for Laparoscopic Spleen-Preserving Distal Pancreatectomy | NCT06167421 | Pancreatic Tumo... Pancreatic Neur... Solid Pseudopap... | Laparoscopic sp... Laparoscopic sp... | 18 Years - 70 Years | Fudan University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
